Bayer's Jivi Receives Positive Recommendation for Expanded Indication in Europe to Include Children Aged 7 and Above.
Securing a New Option in the Pediatric Hemophilia Market
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the extension of the indication for Bayer AG's Jivi (damoctocog alfa pegol), a treatment for Hemophilia A, to include children aged 7 and above. This recommendation represents a regulatory milestone aimed at expanding clinical benefits to a broader pediatric patient population, lowering the existing treatment age from 12 years. Upon receiving final approval from the European Commission (EC), Bayer will be able to further strengthen its competitive position in the European market for extended half-life Factor VIII products for severe pediatric patients. In particular, it holds significant market value as it provides a treatment option with reduced dosing frequency for pediatric patients for whom prophylactic therapy is essential.
Clinical Data Demonstrating Safety and Efficacy
This regulatory progress is based on integrated data from the Alfa-PROTECT and PROTECT Kids studies, Phase 3 trials that evaluated the efficacy and safety of Jivi in children aged 7 years and older. In the clinical trials, Jivi effectively controlled bleeding frequency in pediatric patients and demonstrated good tolerability, successfully meeting the primary endpoints of the Phase 3 trial. However, in infants and young children under the age of 7, the development of anti-PEG antibodies and associated hypersensitivity reactions related to the PEGylated component were observed, leading to their exclusion from the indication. This is analytically significant in that it establishes a clear and safe clinical boundary, considering the drug's mechanism of action and the immune system development of pediatric patients.
Bayer's Survival Strategy in the Competitive Hemophilia Market
The global Hemophilia A market is currently characterized by intense competition for market share among Sanofi's Eloctate and Altuviiio, and Roche's non-factor therapy Hemlibra. Jivi is a PEGylated recombinant Factor VIII product with a significantly extended half-life, providing improved convenience by reducing the frequency of intravenous injections to once or twice a week compared to conventional standard therapies. Bayer is currently experiencing a slowdown in sales of its hemostasis portfolio in the United States and Europe due to strong pressure from competing products. Therefore, this expanded pediatric indication can be seen as an essential defensive strategy to defend its position in the European market and secure new prescriptions, following FDA approval in May 2025 in the United States.
Long-Term Commercial Value from Expanded Prescription Base
The EMA's recommendation goes beyond simply expanding the indication and is expected to be a significant turning point that will enable Bayer's blood products division to achieve long-term stability. Pediatric patients tend to have a very high retention rate, as they are likely to continue long-term treatment without switching medications once they start prophylactic therapy. Accordingly, if Jivi's European prescription base expands into the pediatric area, it can be expected to have a lock-in effect, preventing patients from switching to competitors' non-factor therapies or gene therapies. Ultimately, it is predicted that Bayer will be able to gain an advantage in price negotiations and national reimbursement listings by demonstrating strong prophylactic efficacy in pediatric patients.
With Bayer AG (BAYN.DE)'s Jivi receiving a recommendation for expanded approval from the EMA CHMP based on Phase 3 clinical data in children aged 7 and above, final approval from the European Commission is highly likely, paving the way for commercialization in pediatric patients. This secures a key weapon for Bayer to defend its market share in the pediatric prophylactic therapy market, countering the offensive from competitors such as Roche's Hemlibra and Sanofi's Altuviiio in the global Hemophilia A market, which is estimated at approximately $14 billion by 2025. From a researcher's perspective, it holds academic value in overcoming the anti-PEG antibody-related safety issues observed in children under the age of 7 and in elucidating the limits of immunogenicity in pediatric patients. In the medium to long term, the patient lock-in effect secured from childhood will play a buffering role in mitigating Bayer's declining sales in the blood products division.
Source: EMA (ema)